Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

500
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
500
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

525
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
525
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A Proposed Anatomical-Fluoroscopic Workflow to Identify the Optimal Split Line for Leaflet Modification in Redo-TAVR.

JACC. Cardiovascular interventions·2026
Same author

Flow Normalization and Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement Across Low-Flow Aortic Stenosis Phenotypes.

The American journal of cardiology·2026
Same author

Differential effect of chronic kidney disease on right-sided extravalvular damage in low-flow, low-gradient aortic stenosis.

The Journal of invasive cardiology·2026
Same author

Prognostic Impact of Neurologic Events After Transcatheter Aortic Valve Implantation According to Their Timing.

The Canadian journal of cardiology·2026
Same author

Left ventricular remodeling after redo transcatheter aortic valve replacement: A first-in-human computed tomography analysis.

Journal of cardiovascular computed tomography·2026
Same author

Clinical Differences and Disparities Among Men and Women With Acute Myocardial Infarction-Related Cardiogenic Shock Undergoing Percutaneous Coronary Intervention.

The American journal of cardiology·2026

関連する実験動画

Updated: May 6, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

10.1K

心臓 ショック に よっ て 複雑 に なっ た 急性 心筋 梗塞 の 侵襲 的 な 治療:アメリカ 心臓 協会 の 科学 的 な 声明

Timothy D Henry, Matthew I Tomey, Jacqueline E Tamis-Holland

    Circulation
    |March 4, 2021
    PubMed
    まとめ

    心臓発作後の心臓ショック (CS) は致命的です 早期再血管化は生存率を改善しますが,急性心筋梗塞のCSではよりよい結果を出すために,機械循環支援 (MCS) のような新しい戦略は標準化されたプロトコルが必要です.

    キーワード:
    AHAの科学発表心臓キャセテリゼーション心筋梗塞ショック,心臓

    さらに関連する動画

    An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
    07:15

    An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

    Published on: July 31, 2019

    9.9K
    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
    08:15

    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

    Published on: January 31, 2020

    8.9K

    関連する実験動画

    Last Updated: May 6, 2026

    Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
    13:51

    Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

    Published on: November 11, 2018

    10.1K
    An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
    07:15

    An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

    Published on: July 31, 2019

    9.9K
    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
    08:15

    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

    Published on: January 31, 2020

    8.9K

    科学分野:

    • 心臓病科
    • 介入心臓科
    • クリティカル ケア 医療

    背景:

    • 心臓発作 (CS) は急性心筋梗塞 (AMICS) の主要な死因である.
    • 早期の血管再生は生存に有益ですが 死亡率は安定しています
    • 最近のガイドラインでは,標準化されたCSプロトコルと機械的循環支援 (MCS) を推奨しています.

    研究 の 目的:

    • AMICSの介入管理のためのベストプラクティスを概説する.
    • MCSの使用とタイミングの不一致を解決する.
    • 現代の治療戦略の指針を提示する.

    主な方法:

    • 現在の文献とガイドラインのレビュー
    • 冠動脈再血管化の技術についての議論
    • 循環器のメカニカルサポート (MCS) 装置の実装の分析

    主要な成果:

    • AMICS管理の実践パターンは大きく異なります.
    • AMICSにおけるMCSの死亡率の利点は,さらなるランダム化臨床試験の検証を必要とする.
    • 標準化されたプロトコルは 最適な患者ケアに不可欠です

    結論:

    • AMICSの現代的な介入管理には,標準化されたアプローチが必要です.
    • MCSの最適な使用とタイミングは重要です
    • 心臓発作によるAMICSには特別な注意が必要である.